FDA advisory panel to decide on compounding of synthetic peptides amid safety concerns

The FDA advisory committee is meeting to consider whether compounding pharmacies should be allowed to manufacture seven specific synthetic peptides. Use of these peptides has grown in the United States, but safety and efficacy data remain limited, making the issue politically charged.

The panel brings together long‑time FDA scientists and newer members with prescribing experience, highlighting a potential clash over how broadly peptide access should be regulated. Their decision could set a precedent for how compounded peptide products are treated under federal law.

The newsletter also mentions other biotech developments, including Revolution Medicines advancing a pancreatic cancer drug toward approval, Merck’s Ebola vaccine showing promise in the DRC outbreak, and Verdiva Bio hiring a new chief medical officer. However, the central story is the FDA’s pending ruling on peptide compounding.